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Abstract 
Background: The endocannabinoid (EC) system is well characterized in the 
central nervous system but scarcely studied in peripheral organs. In this pa-
per, we newly identify the effect of the EC anandamide (AEA) upon renal 
proximal tubule cells. Methods: Measurement of lactate dehydrogenase 
(LDH) release after treatment of primary renal proximal tubule cells (RPTEC) 
and renal carcinoma cell line (Caki-1) with AEA, arachidonic acid (AA), 
ethanolamide (EtAm), EC receptor CB1 antagonist (AM251), CB2 receptor 
antagonist (SR144528), TRPV1 receptor antagonist (capsazepine), degrada-
tion enzyme fatty acid amide hydrolase (FAAH) antagonist (URB597), anti-
oxidants GSH-EE; Trolox, GSH depletor BSO, membrane cholesterol depletor 
(MCD), apoptosis inhibitor zVAD, necroptosis inhibitor Nec-1 or ferroptosis 
inhibitor Fer-1. Western blot and qRT-PCR analysis plus determination of 
reactive oxygen species (ROS) via H2-DCFDA were performed. Histology for 
EC enzymes, N-acetylphosphatidylethanolamine-hydrolyzing phospholipase 
D (NAPE-PLD) and FAAH, as well as the determination of physiological le-
vels of ECs in human and rat renal tissue via liquid chromatography were 
conducted. Results: AEA both dose- and time-dependently induces cell death 
in RPTEC and Caki-1 within hours, characterized by cell blebbing, not influ-
enced by blocking the described EC receptors by AM251, SR144528, capsaze-
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pine or FAAH by URB597 or MCD. Cell death is mediated via ROS. There is 
no difference found in the histology of the enzymes FAAH and NAPE-PLD in 
human renal tissue with interstitial nephritis. Blocking of apoptotic, necrop-
totic or ferroptotic cell death does not lead to a reduction in LDH release in 
vitro. Conclusion: The endocannabinoid anandamide induces cell death in 
renal proximal tubule cell in a time- and dose-dependent manner. This path-
way is mediated via ROS and is independent of cannabinoid receptors, mem-
brane cholesterol or FAAH activity. 
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1. Introduction 
Endocannabinoids (ECs) are endogenous lipids that have been gaining more in-
terest during the last years as the exogenous equivalent is known as Δ9-THC 
(Δ9-tetrahydrocannabinol), the active psychotropic natural product of Cannabis 
[1]. 
The EC system is extensively studied in immune system function and the cen-
tral nervous system, as it is involved in memory processing, regulation of pain, 
neuroprotection, addiction and appetite [2] [3] [4]. In peripheral organs like the 
liver, the endocannabinoid system contributes to cell death mechanisms that 
involve cyclooxygenase 2 (COX2) [5], as well as hepatic injury and fibrogenesis 
[6] [7]. The EC anandamide (AEA) can reach an intracellular level of up to 50 
µM upon proinflammatory activation of cells [8] [9]. 
In renal tissue, the EC system has gained more interest during the last years 
and a role for the cannabinoid receptor 1 (CB1) in pathogenesis of interstitial fi-
brosis has been proposed, while the cannabinoid receptor 2 (CB2) has been re-
garded as protective in chronic renal disease [10] [11]. Ritter and colleagues 
proposed in 2016 the necessity of further studies to define and exploit the role of 
the EC system in the kidney [12]. In this study, we considered renal disease 
models resulting in cell loss, like nephritis or ischemic damage during kidney 
transplantation as well as a renal cell carcinoma (RCC). Understanding those 
mechanisms resulting in cell loss and the possible involvement of the EC system 
is an important step towards understanding disease entities. 
For a long time, apoptosis or necrosis were the only forms of cell death known. 
Currently, processes not classified as apoptosis or necrosis are referred to as re-
gulated necrosis [13]. The identification of several other pathways leading to cell 
death, besides apoptosis and necrosis, has evolved during the last decade and is 
still growing. The recently identified cell death pathways in renal tissue are 
apoptosis, necroptosis and ferroptosis [14] [15] [16]. 
Apoptosis is cell death mainly regulated via caspases that determine cellular fate 
and can be subdivided into an intrinsic (regulated via cellular stress stimuli) and ex-
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trinsic pathway (mediated via death receptors like fatty acid synthase receptor (FasR), 
tumor necrosis factor receptor (TNFR) or TNF related apoptosis inducing li-
gand-receptor (Trail-R)) [17]. zVAD (z-Val-Ala-Asp-(OMe)-Fluoromethyl Ke-
tone) is a selective caspase inhibitor and, therefore, used to block apoptotic cell 
death. 
Necroptosis is mediated by serine-threonine kinase receptor-interacting pro-
tein 1 (RIP1) and RIP3. RIP1 can selectively be blocked by necrostatin-1 (Nec-1) 
[18] [19]. 
Ferroptosis is associated with: ROS accumulation, activation of mitogen acti-
vated protein kinases (MAPK), release of arachidonic acid metabolites, gluta-
thione (GSH) dependence as well as small mitochondria [20], and can be 
blocked by Ferrostatin-1 (Fer-1) through the reduction of lipid oxidation [15]. 
Hepatic cell death upon anandamide (AEA) treatment has been shown to be 
cannabinoid receptor-independent, as G protein-coupled receptors CB1, CB2 
and transient receptor potential vanilloid receptor 1 (TRPV1) are not involved 
[21]. 
In this manuscript, we identify the effect of the endocannabinoid AEA upon 
renal proximal tubule cells. 
2. Materials and Methods 
2.1. Cell Culture and Treatment 
Caki-1 cells (Caki-1) were kindly provided by Prof. Dr. Grünewald and were 
cultured in DMEM (Invitrogen, Darmstadt, Germany) supplemented with 10% 
FCS (PAN Laboratories, Aidenbach, Germany) and 1% Penicillin/Streptomycin 
(Invitrogen). Primary renal proximal tubule epithelial cells (RPTEC; Lonza, Ba-
sel, Switzerland) were cultured in REBM (Lonza) at 37˚C and 5% CO2. For all 
experiments, cells were grown to a confluency of 80% and serum-starved prior 
to the experiment. Cells were treated with AEA (Cayman Chemicals, Ann Arbor, 
USA) or vehicle (ethanol; 0.1% final concentration). Where indicated, cells were 
pretreated with AM251 (CB1 receptor antagonist, 1 µM) from Tocris (Wiesba-
den, Germany); SR144528 (CB2 receptor antagonist, 1 µM), Capsazepine 
(TRPV1 receptor antagonist, 25 µM), Trolox (antioxidant, 100 µM), Necrosta-
tin1 (Nec-1, necroptosis inhibitor, 1 µM), Ferrostatin1 (Fer-1, ferroptosis inhi-
bitor, 60 nM), zVAD (caspase inhibitor, 25 µM), arachidonic acid (25 µM), 
ethanolamine (25 µM), URB597 (FAAH inhibitor, 10 µM), all from Cayman 
Chemicals; glutathione reduced ethyl ester (antioxidant, 4 mM), buthionine sul-
foximine (GSH depletor, 100 µM), methyl-β-cyclodextrin (membrane cholester-
ol depletor, 1 mM), ActD (Actinomycin D, 0.4 µg/ml), Tnf alpha (Tumor necro-
sis factor alpha, 40 ng/ml), TritonX (0.1%); and H2O2 (1 mM), all from Sig-
ma-Aldrich (Deisenhofen, Germany). Cell treatment was based on the manu-
facturers’ instructions and literature [5] [22] and was tested. Each concentration 
of inhibitors was adapted according to the cell types used by previously per-
formed dose-response experiments. 
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2.2. Cell Death Determination 
Detection of cell death was performed using the cytotoxicity detection kit (Roche 
Applied Sciences, Mannheim, Germany) to measure lactate dehydrogenase 
(LDH) release. 10 µL of cell culture free medium were added to 90 µL of LDH 
reaction mixture. After an incubation time of 20 minutes in the dark, the assay 
was measured at 490 nm on a 96 well microtiter plate with the help of an ELISA 
reader (SPECTROstar Omega, BMG Labtech, Ortenberg, Germany). As a nega-
tive control culture medium was used-The negative control was acquired by 
adding 1 µl TritonX to the cells, thereby, causing cell death and subsequent rup-
ture of cellular membranes, therefore representing the 100% LDH release control. 
2.3. Experimental Kidney Transplantation 
Allogeneic renal transplantation was performed in male Dark Agouti (DA 
(RT1av1)) to Lewis (LEW (RT1l)) rat strain combination at an age of about 2 
month, while transplants between Lewis rats (isotransplantation) and 
non-transplanted Lewis rats served as control [23]. Recipients of isografts were 
sacrificed 10 days after transplantation; recipients of allografts were sacrificed 6 
to 8 days after transplantation. Kidneys were removed and snap-frozen followed 
by HPLC-MS/MS analysis. Range of morphological alterations in allo- and iso-
transplanted kidneys were equivalent to those published before [23]. 
Animal experiments were approved, according to the German national laws 
for animal protection, by the local ethics committee (V54-19c20-15(1) GI20/27: 
36/2004; 23/2008; 51/2010). 
2.4. FACS 
APC AnnV and PI staining was performed according to the manufacturers pro-
tocol (BD Pharmingen). APC AnnV was detected with a 633 nm FACS filter, 
whereas PI was detected with a 488 nm FACS filter. 
Confluent and treated cells were washed twice with PBS, detached from the 
cell culture plates and washed again with PBS. The pellet was resuspended in 500 
µl of 1× binding buffer. To the stain cells, 3 µl APC AnnV and 5 µl PI supplied 
staining solution was added and the solution was kept in the dark. As positive 
control, Jurkat cells were treated with 100 ng/ml alpha-FAS for 4 h to induce 
apoptosis. The cells were then stained as described above. Flow cytometry was 
performed by FACSCanto I (Becton Dickinson) and the obtained data was ana-
lysed using FlowJo (Tree Star). 
2.5. Human Biopsies 
Formalin-fixed and paraffinized human renal biopsies were selected from the 
archives of the Department of Pathology, University Hospital of Cologne, Ger-
many. Histologic evaluation was based on independent analyses by two staff pa-
thologists (J.W.U. Fries and H. Löser) using Haematoxylin-Eosin (H&E)-stained 
paraffin sections. Since human renal tissue was used, procedures were followed 
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as outlined in accordance with ethical standards formulated in the Helsinki 
Declaration 1975 (and revised in 1983), or the Declaration of Istanbul (for con-
trol transplant biopsies), respectively, with pre-approval by the Ethics Commit-
tee at the University Hospital, Cologne (reference number: 09-232). Informed 
consent forms from each patient or parents of children were obtained. 
2.6. Histology 
Histology was performed as previously published [24]. Primary antibodies against 
N-acetylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD, 
AEA formation enzyme, Sigma-Aldrich) and fatty acid amide hydrolase (FAAH, 
AEA degradation enzyme, Cayman Chemicals) were used and evaluated using a 
Leica DM IL (Leica, Wetzlar, Germany). 
2.7. Liquid Chromatography 
Liquid chromatography was performed as previously published [25]. Briefly, for 
LC/MRM analysis of human biopsy samples, 20 µl of the sample were injected 
and separated in a Phenomenex Luna 2.5 µm C18(2)-HST column and a 
pre-column (C18, 4 × 2 mm2). The separated samples were analysed using MRM 
with a 5500 QTrap triple-quadrupole linear ion trap mass spectrometer with a 
Turbo V Ion Source (AB SCIEX). Precursor and product ion m/z transitions 
were used for the detection of AA, AEA and 2-AG respectively as 303 > 311, 
348.3 > 62.3, 379.1 > 287.2. 
For HPLC-MS/MS analysis of experimental kidney transplantation in rat 
samples, 10 µl of the sample were injected and separated in a ACE 3 C8, 100 × 
2.1 mm, 3 µm with guard column. The MS system used was a triple quadrupole 
ion-trap 4000 QTRAP mass-spectrometer (Applied Biosystems) equipped with 
Turbo Spray ionisation interface. 
Precursor and product ion m/z transitions were used for the detection of OEA, 
PEA, AEA and 2-AG respectively as 326.30 > 62.10, 300.10 > 62.10, 348.1 > 62.10, 
379.10 > 287.50. 
The methods were chosen according to the expertise of the participating re-
searchers AEA and 2-AG present comparable precursor and product ion m/z 
transitions (LC/MRM by LB, BL; HPLC-MS/MS by DAB, SS, CAO). 
2.8. Reactive Oxygen Species (ROS) 
Detection of ROS was performed as previously described [26]. 
5-(and-6)-Chloromethyl-2‘,7‘-Dichlorodihydrofluorescein Diacetate, Acetyl Es-
ter (CM-H2DCFDA; ThermoFisher Scientific, Darmstadt, Germany) was loaded 
and ROS formation measured using excitation and emission filters of 485nm 
and 535nm (Leica DM IL, Leica, Wetzlar, Germany), respectively. 
2.9. RT-PCR and Quantitative Real-Time PCR (qRT-PCR) 
RT-PCR and qRT-PCR were performed as previously published [27] [28]. 
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qRT-PCR was evaluated using the ΔΔ-ct method, as described in User Bulletin 2 (PE 
Applied Biosystems, Darmstadt, Germany). H2O was used as negative control. Pri-
mers were obtained by Invitrogen for β-actin (forward: 
TTGGCAATGAGCGGTTCCGCTG, reverse: GACAGCACTGTGTTGGCGTA), 
CB1 (forward: CATCACCACTGACCTCCTGT, reverse: 
TTGTCTCCCGCAGTCATCTT), CB2 (forward: CTGCGCTATCCACCTTCCTA, 
reverse: CGGAAAAGAGGAAGGCGATG), TRPV1 (forward: 
CGCTGATTGAAGACGGGAAG, reverse: GCATGTTGAGCAGGAGGATG), 
FAAH (forward: CTGCTCTGGACTTGAATGCC, reverse: 
CCCCAAAGTAGCCCCTGTAA-3’). PCR was performed with a number of 40 
cycles, starting with a denaturation temperature of 95˚C for 15 seconds, an an-
nealing temperature of 55˚C for 1 minute followed by an elongation temperature 
of 72˚C for 30 seconds. A final extension step for 10 minutes at 72˚C was chosen 
before cooling to 4˚C. 
2.10. Western Blot 
Western blot analysis was performed as previously described [29]. Briefly, 20 µg 
protein determined with Bradford (Sigma-Aldrich, Deisenhofen, Germany) per 
sample were loaded into a 10% polyacrylamide gel. Following gel electrophoresis, 
the gel was blotted onto a nitrocellulose membrane and blocked in 3% TBS-T 
milk. Antibodies against CB1, CB2, TRPV1 (Biorbyt, Cambride, UK) and PARP, 
cleaved caspases 3 and β-actin (Cell Signalling, Danvers, USA) were used in a 
dilution of 1:1000. All antibodies were tested for specificity with peptides cor-
responding to the peptide sequences used for immunization (Santa Cruz Bio-
technology, Santa Cruz, CA). HRP-labeled secondary antibodies were used in a 
concentration of 1:10.000. 
2.11. Statistical Analysis 
All data represents the mean of three independent experiments. Densitometric 
analysis was performed with the ImageJ program, according to the manufactur-
er’s protocols, to quantify Western blots. GraphPrism 5 (GraphPad Software, La 
Jolla, Calif., USA) was used to calculate statistical significances with the Stu-
dent’s unpaired t-test (*p < 0.05, **p < 0.01, ***p < 0.001). 
3. Results 
3.1. AEA Mediates Cell Death in RPTEC and Caki-1 in a Dose  
Dependent Manner 
It is known that AEA can induce cell death in hepatic stellate cells [21]. 
LC/MRM measurements of human renal biopsies and HPLC-MS/MS analyses in 
experimental rat renal allografts and isografts (Suppl. Figure 2) revealed the 
presence of AEA and 2-AG in renal tissue. This is a crucial method to introduce 
further research in the field of EC signaling within renal tissue. Nevertheless, 
these analyses only represent the physiological levels of EC within the tissue, 
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while a pathological EC increase is not within the determination. 
To further support the observation of an expression of EC signaling by liquid 
chromatography, the effect of AEA within the renal cell lines Caki-1 and RPTEC 
was considered. Treatment with different concentrations of AEA over time show 
rapid and dose-dependent induction of LDH release in Caki-1 and RPTEC 
(Figures 1(a)-(d)). Additionally, degradation products of AEA, ethanolamide  
 
 
 
Figure 1. Time- and dose-dependent LDH release and morphological changes in RPTEC and Caki-1 after AEA treatment. (a) 
Caki-1: dose-dependent LDH release after 2 h AEA treatment; (b) Caki-1: dose-dependent LDH release after 4 h AEA treatment; 
(c) RPTEC: dose-dependent LDH release after 2 h AEA treatment; (d) RPTEC: dose-dependent LDH release after 4 h AEA treat-
ment. As positive control, ActD (0.4 µg/ml) Tnf alpha (40 ng/ml) for 16 h were used and as 100% LDH release control 1 µl Tri-
tonX was added to the cells. EtAm and AA were used to control the effect of degradation products of AEA. Vehicle control etha-
nol (untreated) was used as negative control. Unpaired Student’s t-test against 100% LDH release control was performed and all 
differenced in values are statistically significant; (e) Untreated Caki-1 with normal morphology; (f) 4 h 70 µM AEA in Caki-1 
showing blebbing, detachment of cells and loss of cell-cell contact; (g) Untreated RPTEC with normal morphology; (h) 4 h 70 µM 
AEA in RPTEC cells showing detachment of cells, round morphology and loss of cell-cell contacts. *=p > 0.5, **=p > 0.05, ***=p > 
0.001. 
50µm 50µm
50µm50µm
(e) (f)
(h)(g)
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(EtAm) and arachidonic acid (AA) were used for treatment as well to prove that 
the degradation products of AEA are not toxic to the cells, as it is known from 
literature that free fatty acids can present a source of cellular toxicity [30] [31] 
[32]. 
RPTEC have a higher sensitivity against AEA-induced cell death as the 
dose-dependent LDH release is already visible after 2 h of treatment. EtAm as 
degradation product of AEA, as well as ethanol (untreated vehicle control), did 
not cause any increase in LDH release. We observed an increase in LDH release 
after treating RPTEC with 25 µM AA up to 30% compared to positive control 
TritonX. RPTEC, as primary cells, seem to have a higher susceptibility for LDH 
loss after AA treatment. Compared to AEA treatment, LDH release does not in-
crease over time but stays constant at approximately 30% (data not shown). 
To further confirm the findings obtained with LDH release and to represent 
the findings with another method, time-lapse videos were produced during 4 h 
of treatment with 70 µM AEA (Figures 1(e)-(h)) in both Caki-1 and RPTEC. 
The characteristically morphological blebbing of the cells indicates a 
non-apoptotic type of cell death (Figure 1(f), Figure 1(h)). 
LDH release and morphology of Caki-1 and RPTEC led to the conclusion that 
renal cells undergo cell death upon AEA treatment. As an increase in the con-
centration of AEA leads to an exponential increase in LDH release, it is not likely 
that the cell death results from free acid. Additionally, treatment with the degra-
dation products of AEA, namely arachidonic acid and ethanolamide, or ethanol 
as a vehicle control did not lead to an increase in LDH release above vehicle 
control levels. An influence upon cell death due to higher free acids or alcohol is 
not likely to cause increased cell membrane damage. 
Since the effect of AEA in the following experiments should result in clear 
readout of LDH release, the concentration of 70 µM AEA was used for all other 
experiments as it obtained the best signal-to-noise ratio. The LDH release 
amounts to approximately 70% and therefore represents an adequate level of 
cellular leakage. Additionally, higher doses of AEA can be found in proinflam-
matory processes within organs and are pathologically possible. 
3.2. Cannabinoid Receptors in Caki-1 and RPTEC 
Cannabinoid receptors are expressed in several peripheral organs at the mRNA 
and protein levels. Here, cannabinoid receptor mRNA and protein expression 
were investigated in Caki-1 and RPTEC. PCR results lead to the conclusion that 
Caki-1 and RPTEC express CB1, CB2 and TRPV1 (Figure 2(b)). qRT-PCR re-
sults in Caki-1 and RPTEC underline the results of the PCR analysis. There is 
transcription of the most common cannabinoid receptors CB1, CB2 and TRPV1 
(Figure 2(a)). 
Western blot analysis revealed that Caki-1 express CB2 irrespective of the 
treatment with 70 µM AEA for 4 h. An increase in TRPV1 protein was observed 
after AEA treatment. There is no protein for CB1 detectable (Figure 2(c), Fig-
ure 2(d)). TRPV1 protein is not found in RPTEC. After treatment with 70 µM  
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Figure 2. Western blot and qRT-PCR analysis of RPTEC and Caki-1 treated with 70 µM AEA for 4 h. (a) 
qRT-PCR of CB1, CB2, TRPV1, β-actin as control in RPTEC and Caki-1. Vehicle control ethanol (un-
treated) was used as negative control. There is a significant decrease in CB1 receptor expression in RPTEC, 
whereas CB2 expression is significantly increased. No significant expression difference of TRPV1; (b) 
RT-PCR product of CB1 (product size 156 bp), CB2 (product size 208 bp), TRPV1 (product size 246 bp), 
β-actin control (product size 133 bp) in RPTEC and Caki-1; (c) Densitometry of Western blots of Caki-1 
with a significant increase of CB2 and TRPV1 treated with 70 µM AEA; (d) Western blot of CB1 (55 kDa), 
CB2 (47 kDa), TRPV1 (80 kDa), and β-actin (46 kDa) as control in Caki-1. CB1 is marginally transcribed 
in Caki-1; (e) Densitometry of Western blots of RPTEC with significant increase of CB1 and CB2 after 4 h 
treatment with 70 µM AEA. All values under the 100% control of β-actin are not considered for evalua-
tion; (f) Western blot of CB1, CB2, TRPV1, β-actin as control in RPTEC. TRPV1 is not transcribed in 
RPTECs and CB1 cannot be found in untreated RPTEC. *=p > 0.5, **=p > 0.05, ***=p > 0.001. 
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for 4 h, CB1 protein expression increases as compared to untreated RPTEC. CB2 
protein is detectable in treated and untreated cells. (Figure 2(e), Figure 2(f)). 
3.3. AEA-Induced Cell Death in Caki-1 and RPTEC Is Not Mediated  
via Cannabinoid Receptors or FAAH 
As cannabinoid receptors are expressed by Caki-1 and RPTEC, the dependence 
of LDH release and cell death was analyzed by selectively blocking: CB1 with 
AM251, CB2 with SR144528, TRPV1 by capsazepine and the AEA degradation 
enzyme fatty acid amide hydrolase (FAAH) by URB597 (Figure 3(a), Figure 
3(b)). 
LDH release is significantly increased in cells pretreated with the CB1 blocker 
(AM251) or the CB2 blocker (SR144528) and followed by subsequent AEA 
treatment in Caki-1 cells. Blocking of TRPV1 (capsazepine) and FAAH (URB597) 
did not change the LDH release as compared to AEA treatment alone (Figure 
3(a)). LDH release in RPTEC is not altered when CB1 is blocked by AEA treat- 
 
 
Figure 3. LDH release by Caki-1 and RPTEC after blocking of cannabinoid receptors, FAAH and block of apoptosis, necroptosis 
and ferroptosis. (a) LDH release of Caki-1 after blocking with URB597 (FAAH receptor block, 10 µM, 1 h), Cap (capsazepine, 25 
µM, 1 h, TRPV1 antagonist), SR (SR144528, 1 µM, 1 h, CB2 antagonist), AM251 (1 µM, 1 h, CB1 antagonist); (b) LDH release by 
RPTEC after blocking with URB597 (FAAH receptor block, 10 µM, 1 h), Cap (capsazepine, 25 µM, 1 h, TRPV1 antagonist), SR 
(SR144528, 1 µM, 1 h, CB2 antagonist), AM251 (1 µM, 1 h, CB1 antagonist); (c) LDH release by RPTEC after block of apoptosis 
(25 µM, 1 h, zVAD), necrosis (1 µM, 1 h, Nec) and ferroptosis (60 nM, 1 h, Fer), followed by 4 h 70 µM AEA treatment. For 100% 
LDH release as control 1 µl TritonX was added to the cells. Positive control using ActD and Tnf alpha, 100% LDH release as con-
trol 1 µl TritonX was added to the cells. Vehicle control ethanol (untreated) was used as negative control. *=p > 0.5, **=p > 0.05, 
***=p > 0.001. 
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ment. The application of inhibitors of CB2, TRPV1, and FAAH after AEA 
treatment leads to a significant increase in LDH release (Figure 3(b)). 
AEA-induced cell death seems to be independent of the known cannabinoid re-
ceptors and FAAH. It is possible that the increase in LDH release and therefore 
the cell death induced by the inhibitors alone can be explained by the protective 
functions of cannabinoid receptors and by the role of FAAH in the metabolism 
of arachidonic acid. 
3.4. AEA-Induced Cell Death Depends on ROS but Not on  
Membrane Cholesterol 
As cannabinoid receptors and FAAH do not participate in cell death processes in 
Caki-1 or RPTEC, the underlying cause of cell death was investigated. As cell 
death is often related with an increase of ROS or membrane cholesterol, both 
systems were modified with membrane cholesterol depletor (MCD), antioxi-
dants (GSH-EE, Trolox), or GSH depletor (BSO). Afterwards, the LDH release 
was analyzed (Figure 4(a), Figure 4(b)). 
Upon single treatment with MCD, Trolox and BSO, Caki-1 and RPTEC show 
LDH release comparable to untreated cells. Treating Caki-1 with MCD, Trolox 
or GSH-EE together with 70 µM AEA for 4 h resulted in a significant increase of 
LDH release. The LDH release of Caki-1 treated with BSO and AEA versus 
RPTEC treated with MCD and AEA were not significantly different in compari-
son with AEA treated cells alone (Figure 4(a)). 
LDH release by RPTEC after GSH-EE treatment is slightly increased to ap-
proximately 37%. Pretreatment of RPTEC with GSH-EE or BSO and AEA over 4 
h lead to a significant increase of LDH release. Treating RPTEC with Trolox and 
70 µM AEA for 4 h significantly reduced the LDH release towards the control 
level of LDH release found in untreated RPTEC (Figure 4(b)). 
To verify these results, we used H2DCFDA, a well-known method to visualize 
ROS formation within the cytoplasm by fluorescence microscopy. We per-
formed H2DCFDA in RPTEC (Figure 4(c), Figure 5). Results show that there is 
a significant increase of H2DCFDA signal after treatment of RPTEC with Trolox 
and 70 µM AEA over 4 h (Figure 4(c)). Additionally, the H2DCFDA signal sig-
nificantly decreases after treatment with BSO and 70 µM AEA over 4 h, which 
reflects the results of LDH release. Pretreatment with GSH-EE in RPTEC did not 
lead to any significant changes of the H2DCFDA signal. 
3.5. AEA-Induced Cell Death in RPTEC Cannot Be Blocked by  
Common Cell Death Inhibitors 
To characterize the dominant type of cell death in RPTEC, apoptosis was 
blocked by zVAD, whereas necroptotic cell death was prevented by Necrosta-
tin-1 (Nec-1) and ferroptosis by Ferrostatin-1 (Fer-1) (Figure 3(c)). Blocking of 
three known cell death pathways by zVAD, Nec-1, and Fer-1 did not lead to a 
significant reduction of the LDH release in RPTECs. Using a combination of all  
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Figure 4. LDH release by Caki-1 and RPTEC after blocking of ROS and H2DCFA positiv-
ity in RPTEC. (a) LDH release by Caki-1 after GSH-EE (4 mM, 1 h, antioxidant) MCD (1 
mM, 1 h, membrane cholesterol depletor), Trolox (100 µM, 1 h, antioxidant), BSO (100 
µM, 1 h, GSH depletor), followed by 4 h 70 µM AEA treatment displaying a significant 
increase of LDH release after MCD, Trolox and GSH-EE treatment. 100% LDH release as 
control 1 µl TritonX was added to the cells; (b) LDH release by RPTEC after GSH-EE (4 
mM, 1 h, antioxidant) MCD (1 mM, 1h, membrane cholesterol depletor), Trolox (100 µM, 
1 h, antioxidant), BSO (100 µM, 1 h, GSH depletor), followed by 4 h 70 µM AEA treat-
ment. GSH-EE and BSO pretreatment followed by 4 h AEA leads to a significant increase 
in LDH release whereas pretreatment with Trolox and subsequent 4 h AEA treatment 
lead to a highly significant decrease of LDH release in RPTEC. For 100% LDH release as 
control 1 µl TritonX was added to the cells. Positive control using ActD and Tnf alpha, 
100% LDH release as control 1 µl TritonX was added to the cells. Vehicle control ethanol 
(untreated) was used as negative control; (c) Cytoplasmic H2DCFDA positivity in RPTEC 
with a significant increase in H2DCFDA positivity of cells treated with MCD and Trolox 
together with 70 µM AEA compared to 70 µM AEA alone and significant decrease of 
H2DCFDA positivity after BSO pretreatment with subsequent treatment of 70 µM AEA. 
Vehicle control ethanol (untreated) was used as negative control. *=p > 0.5, **=p > 0.05, 
***=p > 0.001. 
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Figure 5. Phase contrast, fluorescence cytoplasmic H2DCFDA and nuclear counterstain 
with DAPI in RPTECs upon 4 h 70 µM AEA treatment with prior block with MCD ( mM, 
1 h), BSO (100 µM, 1 h), GSH-EE (4 mM, 1 h) and Trolox (100 µM, 1 h). There is a re-
duction in cell amount after 4 h 70 µM AEA treatment. Pretreatment with BSO and sub-
sequent AEA treatment lead to a decrease in H2DCFDA positivity as compared to AEA 
alone, whereas Trolox and MCD before AEA treatment leads to an increase in H2DCFDA 
positivity. Vehicle control ethanol (untreated) was used as negative control. 
 
three compounds with an addition of AEA, resulted in a significant increase of 
LDH. 
A combination of components from different cell death pathways seems to be 
most likely. Despite the missing decrease of LDH release after blocking cell death 
pathways, we suggest a ferroptotic component of cell death due to a combination 
of morphological changes, decrease of LDH release after Trolox treatment and 
increase of H2DCFDA after Trolox pretreatment. 
3.6. Acute Renal Injury in Humans 
The endocannabinoid system is a complex metabolic system and the degradation 
of lipids, like AEA, is strictly regulated. Therefore, it is important to determine 
the enzyme production of both synthesis and degradation by NAPE-PLD and 
FAAH in the processing of AEA. 
It is difficult to extrapolate systemic physiological effects of ECs by cell culture 
studies. To analyze the potential pathological importance of this system in dis-
eases with acute renal injury, these two enzymes were studied in two different 
renal disease entities. Using human renal biopsies, control kidneys 
(Suppl.Figure 1(a)-(e)) were compared to those from patients with interstitial 
Phase 
Contrast
H2DCFDA
DAPI
Phase 
Contrast
H2DCFDA
DAPI
Vehicle control BSO Trolox GSH-EEMCD
BSO + 70µM AEA MCD + 70µM AEA GSH-EE + 70µM AEATrolox + 70µM AEA70µM AEA
0.2mm
0.2mm
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nephritis associated with tubulitis, interstitial fibrosis, and tubular atrophy 
(Suppl.Figure 1(f)-(j)). Both enzymes were produced in renal proximal tubuli 
but not in distal tubuli. However, their level remained unchanged in interstitial 
nephritis vs. the control kidneys. 
4. Discussion 
This study newly describes the effect of increased levels of the endocannabinoid 
AEA upon renal proximal tubule cells during proinflammatory processes. Caki-1 
and RPTEC were chosen for two reasons: i) as cell culture models to represent 
renal proximal tubule cells, and ii) to use primary cells that represent a more 
physiological representation of renal morphology. The endocannabinoid AEA 
can be measured under physiological conditions in human and rat renal tissue 
(Suppl.Figure 2). As the EC system is present in renal proximal tubule cells, 
pathological increase of AEA during proinflammatory processes is likely. In 
comparison to other organs, like the liver, kidney cells represent a vast variety of 
different cell types therefore representing one of the most complex organs in 
mammals. A homogenous culture model has the advantage of representing one 
cell type without an effect of dilution due to the different cell regulatory me-
chanisms of numerous cell types. Additionally, it is possible to vary cell culture 
treatments in different concentrations (like the one used in vitro concentration 
of AEA) to ensure an optimal signal-to-noise ratio without fearing an increased 
systemic effect on the respective treatments. 
Compared to hepatic stellate cells, in which AEA induces necrosis [21], renal 
cells undergo cell death via another, more complex mechanism. This cell death is 
dose-dependent and morphologically defined by cell blebbing, which is highly 
characteristic for non-apoptotic cell death. In contrast, cell budding is a charac-
teristic feature of apoptotic cell death [17]. AnnexinV and propidium iodide 
staining and subsequent FACS analyses of RPTEC and Caki-1 did not lead to 
any results (data not shown). Despite several experimental repetitions and a 
functional positive control for Annexin V and propidium iodide (Jurkat cells 
treated with alpha-FAS), cell debris and cell fragments were detectable as soon as 
2 hours after treatment. These findings of cell debris and cell fragments within 
the FACS analyses were approved by time-lapse observations and LDH release of 
RPTEC and Caki-1 cells. Cell blebbing already began within 2 hours after treat-
ment. 
Cell blebbing is a feature of non-apoptotic cell death. The influence of Trolox 
within the cell and the opposite effects of GSH-EE and BSO, respectively, on 
LDH release and rapid ROS formation is an additional aspect pointing towards 
ferroptotic cell death [33]. 
As seen in Figure 4, Trolox and AEA treated RPTEC show a decrease in LDH 
release but an increase in H2DCFDA as compared to AEA treatment alone. Ac-
cording to literature in previous studies in hepatic stellate cells and AEA [21], we 
should expect a decrease in both LDH release and H2DCFDA after treatment of 
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Trolox and AEA. Nevertheless, there seems to be some compensatory effect. 
Even though ROS increases after Trolox and AEA treatment, LDH leakage sig-
nificantly decreases. Caki-1 cells, as a cell line with RCC background, show a 
different behavior towards ROS modulation. There is no significant decrease in 
LDH release measureable after treatment of BSO; GSH-EE or Trolox together 
with AEA. Caki-1 cells seem to be more adept to deal with cellular stress pre-
sented by ROS. 
To further extend our understanding of the potential the role of this system in 
acute renal injury, we analyzed the expression level of NAPE-PLD and FAAH in 
two renal disease entities (Suppl.Figure 1). Surprisingly, we did not find any 
significant changes between the control tissues and the diseased kidneys despite 
inflammatory alterations in interstitial nephritis or immunologic destruction of 
proximal tubuli in rat renal transplants, which is in contrast to the aforemen-
tioned findings after toxic [15] or metabolic [34] tubular injury. 
Martin-Sanchez and colleagues verify ferroptosis as the dominant cell death 
mechanism in acute kidney injury [15]. Acute injury occurring in diabetic 
nephropathy with subsequent tubular inflammation can lead to a local upregula-
tion of the endocannabinoid system [34]. According to the acquired results, our 
data show a non-apoptotic type of cell death which cannot completely be cha-
racterized with the help of the methods utilized. The absence of LDH reduction 
after blocking LDH release with common cell death blockers against apoptosis, 
necroptosis, and ferroptosis does not necessarily lead to rejection of the evidence 
towards the analyzed cell death mechanisms. This could be due to the fact that 
the process of, for example, ferroptotic cell death might be regulated down-
stream of the effect of Fer-1 [33]. 
AEA induces cell death in a dose- and time-dependent manner in renal 
proximal tubule cells. An effect in vitro can be measured at concentrations above 
25 µM. Select 70 µM AEA with an LDH release of 70% is especially important in 
experimental setups modifying ROS or blocking cell death receptors. As the 
baseline LDH release is on average at 12% (which is expected for adherent 
growing cells) selecting AEA levels resulting in an LDH release in between posi-
tive and negative control and biological levels of AEA are increased in proin-
flammatory processes. This effect is not mediated via cannabinoid receptors, 
FAAH or membrane cholesterol but is mediated via ROS. AEA-induced cell 
death leads to a blebbing of cells and additionally to ROS activation, so that fer-
roptotic cell death is most likely. Furthermore, this mechanism is not a general 
response to acute tubular injury but seems to be activated only in very specific 
tubular damage such as inflicted by specific toxins or metabolic alterations. 
In summary, the endocannabinoid AEA induces cannabinoid receptor- and 
membrane cholesterol-independent cell death in renal proximal tubule cells via 
ROS. While AEA can induce cell death, the detailed mechanism behind this 
process has to be further evaluated in the future using newly developed blockers 
and methods to differentiate non-apoptotic cell death mechanisms. 
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Supplementary Figure/Table 
Supplementary Table: 
List of Abbreviations: 
2-AG 2-Arachidonoyl Glycerol 
AA Arachidonic Acid 
ActD Actinomycin D 
AEA Arachidonoyl Ethanolamide 
AnnV Annexin V 
APC Allophycocyanin 
APS Ammoniumpersulfate 
BSO Buthionine Sulfoximine 
CB1 Cannabinoid Receptor 1 
CB2 Cannabinoid Receptor 2 
EC Endocannabinoid 
ET Endothelin 
ETAR Endothelin A Receptor 
EtAM Ethanolamine 
ETBR Endothelin B Receptor 
ET-1 Endothelin-1 
EtOH Ethanol 
FAAH Fatty Acid Amide Hydrolase 
FACS Fluorescence-Activated Cell Sorting 
Fas Fatty Acid Synthase 
Fer-1 Ferrostatin1 
Fig Figure 
GSH-EE Glutathione Reduced Ethyl Ester 
H2DCFDA 2‘,7‘-Dichlorofluorescein Diacetate 
HPLC-MS/MS High-Performance Liquid Chromatography-Tandem Mass Spectrometry 
ko Knockout 
LDH Lactate Dehydrogenase 
MCD Methyl-β-Cyclodextrin 
MAGL Monoacylglycerol Lipase 
NAPE-PLD N-Acetylphosphatidylethanolamine-Hydrolysing Phospholipase D 
Nec-1 Necrostatin1 
ns Not Significant 
Nx 5/6 Nephrectomy 
OEA Oleoylethanolamide 
PEA Palmitoylethanolamide 
ROS Reactive Oxygen Species 
RPMI Roswell Park Memorial Institute 
RPTEC Renal Proximal Tubule Epithelial Cells 
TNFα Tumor Necrosis Factor Alpha 
TRPV1 Transient Receptor Potential Vanilloid Type 1 
wt Wild type 
zVAD Z-Val-Ala-Asp-(OMe)-Fluoromethyl Ketone 
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Supplementary Figure 1. Histology of human renal control tissue (a)-(e) and renal tissue 
with interstitial nephritis and tubulitis with interstitial fibrosis and atrophy (f)-(j) using 
FAAH and NAPE-PLD. (a) control tissue stained against FAAH 1:50; (b) control tissue 
negative control; (c) control tissue stained against FAAH 1:50; (d) control tissue stained 
against NAPE-PLD 1:100; (e) control tissue stained against NAPE-PLD 1:100; (f) intersti-
tial nephritis stained against FAAH 1:50; (g) interstitial nephritis stained against FAAH 
1:50; (h) interstitial nephritis stained against NAPE-PLD 1:100; (i) interstitial nephritis 
negative control; (j) interstitial nephritis stained against NAPE-PLD 1:100. 
 
FAAH NAPE-PLD
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Supplementary Figure 2. LC/MRM analyses in human control tissue (n = 10), RCC (n = 4) and HPLC-MS/MS measurements of 
allogeneic renal transplantation in Dark Agouti (DA (RT1av1)) to Lewis (LEW (RT11)) (n = 4). (a) AEA levels of Dark Agouti to 
Lewis allotransplants, Lewis to Lewis isotransplants and Lewis non-transplanted kidneys; (b) 2-AG levels of Dark Agouti to Lewis 
allotransplants, Lewis to Lewis isotransplants and Lewis non- transplanted kidneys; (c) OEA levels of Dark Agouti to Lewis allo-
transplants, Lewis to Lewis isotransplants and Lewis non-transplanted kidneys; (d) PEA levels of Dark Agouti to Lewis allo-
transplants, Lewis to Lewis isotransplants and Lewis non-transplanted kidneys; (e) AEA levels of control kidney tissue and RCC 
tissue; (f) 2-AG levels of control kidney tissue and RCC tissue; (g) AA levels of control kidney tissue and RCC tissue. Differences 
in the results within each cohort are not significant. 
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